BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox

Dodge & Cox raised its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 315.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,647,091 shares of the company’s stock after purchasing an additional 2,769,654 shares during the period. Dodge & Cox owned 1.52% of BioNTech worth $359,676,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in BNTX. Rhenman & Partners Asset Management AB increased its stake in BioNTech by 0.3% in the second quarter. Rhenman & Partners Asset Management AB now owns 35,870 shares of the company’s stock valued at $3,819,000 after purchasing an additional 120 shares during the last quarter. Kennedy Capital Management LLC increased its position in BioNTech by 0.8% in the 2nd quarter. Kennedy Capital Management LLC now owns 16,422 shares of the company’s stock valued at $1,748,000 after acquiring an additional 127 shares during the period. Probity Advisors Inc. raised its stake in shares of BioNTech by 5.7% during the third quarter. Probity Advisors Inc. now owns 2,506 shares of the company’s stock worth $247,000 after purchasing an additional 135 shares during the last quarter. Mackenzie Financial Corp raised its position in BioNTech by 4.0% during the 3rd quarter. Mackenzie Financial Corp now owns 4,290 shares of the company’s stock worth $418,000 after buying an additional 165 shares during the last quarter. Finally, Banco Bilbao Vizcaya Argentaria S.A. increased its stake in shares of BioNTech by 2.5% during the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 7,653 shares of the company’s stock worth $822,000 after acquiring an additional 186 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

NASDAQ:BNTX opened at $91.19 on Friday. BioNTech SE Sponsored ADR has a fifty-two week low of $79.52 and a fifty-two week high of $124.00. The company has a market cap of $20.53 billion, a P/E ratio of -17.40 and a beta of 1.51. The company has a quick ratio of 7.02, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The firm’s 50 day moving average is $106.43 and its two-hundred day moving average is $102.56.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BNTX shares. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a report on Friday, January 23rd. Leerink Partners downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and set a $113.00 price objective on the stock. in a report on Monday, February 2nd. Canaccord Genuity Group reissued a “buy” rating and issued a $171.00 target price on shares of BioNTech in a report on Wednesday. BMO Capital Markets dropped their price objective on shares of BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, TD Cowen cut their price objective on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.73.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.